Kun Bu | Cardiovascular Pharmacology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Kun Bu
University of South Florida, United States
Kun Bu
Affiliation University of South Florida
Country United States
Scopus ID 57223366298
Documents 10
Citations 68
h-index 6
Subject Area Cardiovascular Pharmacology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0009-0006-9526-3023

Kun Bu is a researcher affiliated with the University of South Florida whose scholarly contributions focus on cardiovascular pharmacology, adverse drug event analysis, transcriptomic profiling, and computational biomedical research. The researcher has participated in multidisciplinary studies examining cardiovascular safety, pharmacovigilance, and molecular mechanisms associated with therapeutic interventions. Through publications indexed in Scopus and peer-reviewed scientific journals, the researcher has contributed to investigations involving electronic health records, FDA adverse event reporting data, and transcriptomic methodologies relevant to cardiovascular medicine and drug safety evaluation.[1]

Abstract

The research activities of Kun Bu are centered on cardiovascular pharmacology, pharmacovigilance, and bioinformatics-driven approaches for evaluating therapeutic safety and adverse cardiovascular outcomes. The researcher has contributed to studies integrating FDA Adverse Event Reporting System (FAERS) data, electronic health records, and transcriptomic analyses to investigate drug-associated cardiovascular risks and molecular mechanisms. These investigations support evidence-based evaluation of therapeutic safety and contribute to broader understanding of adverse cardiovascular reactions associated with clinical pharmacotherapy.[2]

Keywords

  • Cardiovascular Pharmacology
  • Pharmacovigilance
  • FAERS Analysis
  • Transcriptomics
  • Drug Safety
  • Electronic Health Records
  • Cardiovascular Risk Assessment
  • Biomedical Data Science

Introduction

Cardiovascular pharmacology is an evolving scientific discipline that combines molecular biology, clinical medicine, and computational analysis to evaluate therapeutic efficacy and drug-related adverse effects. Modern pharmacovigilance research increasingly incorporates large-scale biomedical databases and transcriptomic profiling to identify molecular pathways associated with cardiovascular complications and treatment outcomes.[3] Kun Bu has contributed to this interdisciplinary field through collaborative investigations involving adverse event reporting systems, transcriptomic analysis, and integrated biomedical data interpretation. The researcher’s work addresses clinically relevant questions associated with cardiovascular safety, adverse drug reactions, and translational pharmacological research within cardiovascular medicine.[1]

Research Profile

Kun Bu is affiliated with the University of South Florida and has developed an academic profile focused on cardiovascular pharmacology and computational biomedical research. According to available Scopus metrics, the researcher has accumulated 68 citations with an h-index of 6, reflecting scholarly visibility and research engagement within the scientific literature.[1] The publication portfolio includes peer-reviewed journal articles in journals such as Pharmaceuticals and Genes, with studies addressing cardiovascular risks associated with COVID-19 therapeutics, dexmedetomidine-associated bradycardia, and statin-associated rhabdomyolysis. These contributions emphasize integration of pharmacological data analytics and molecular profiling techniques.[2]

Research Contributions

One of the researcher’s notable contributions involves integrated analysis of cardiovascular risks associated with COVID-19 therapeutics using FAERS data, electronic health records, and transcriptomics. This work explores potential adverse cardiovascular effects linked to therapeutic interventions and contributes to improved pharmacovigilance methodologies.[2] Additional research examined the association between dexmedetomidine and bradycardia through combined analysis of adverse event reporting systems and transcriptomic profiles. The study contributes to understanding molecular mechanisms and clinical patterns associated with cardiovascular adverse reactions.[3] The researcher has also contributed to investigations regarding statin-associated rhabdomyolysis using transcriptomic and FAERS-based methodologies. Such studies support ongoing evaluation of therapeutic safety and risk stratification within cardiovascular pharmacology and clinical medicine.[4]

Publications

  1. Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals (2026). DOI: 10.3390/ph19040574
  2. The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16060615
  3. The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes (2025). DOI: 10.3390/genes16030248

Research Impact

The scholarly contributions of Kun Bu support the advancement of cardiovascular pharmacology and translational biomedical research. By integrating transcriptomics, adverse event databases, and electronic health records, the researcher’s studies contribute to improved understanding of cardiovascular safety profiles and drug-associated adverse reactions.[2] The citation profile and interdisciplinary publication record demonstrate measurable academic engagement within pharmacology and cardiovascular medicine. The research output contributes to contemporary discussions concerning therapeutic safety assessment and computational approaches in biomedical science.[1]

Award Suitability

Kun Bu’s research profile demonstrates relevance to the International Research Awards on Cardiology & Cardiovascular Medicine through contributions to cardiovascular pharmacology and pharmacovigilance research. The researcher’s investigations address clinically important issues involving drug safety, adverse cardiovascular outcomes, and molecular risk assessment.[3] The combination of peer-reviewed publications, citation metrics, and interdisciplinary scientific methodologies supports recognition within the field of cardiovascular medicine. The researcher’s contributions align with ongoing efforts to improve evidence-based therapeutic evaluation and cardiovascular risk analysis.[4]

Conclusion

Kun Bu has contributed to the interdisciplinary field of cardiovascular pharmacology through research focused on adverse drug event analysis, transcriptomic profiling, and integrated biomedical data interpretation. The researcher’s publication record demonstrates engagement in clinically relevant investigations involving cardiovascular risk assessment and pharmacovigilance. These scholarly contributions support ongoing advancement in cardiovascular medicine and evidence-based therapeutic safety evaluation.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Kun Bu, Author ID 57223366298. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57223366298
  2. Zhu, X., Kuppa, S. A., Umeukeje, G., Morris, R., Bui, L., Bu, K., Zhang, J., Wei, J., & Cheng, F. (2026). Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. Pharmaceuticals. DOI: https://doi.org/10.3390/ph19040574
  3. Morris, R., Kuppa, S. A., Zhu, X., Bu, K., Han, W., & Cheng, F. (2025). The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes. DOI: https://doi.org/10.3390/genes16060615
  4. Morris, R., Bu, K., Han, W., Wood, S., Hernandez Velez, P. M., Ward, J., Crescitelli, A., Martin, M., & Cheng, F. (2025). The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles. Genes.
    DOI: https://doi.org/10.3390/genes16030248

Michael Keller | Cardiac Surgery | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Michael Keller
Virginia Commonwealth University, United States
Michael Keller
Affiliation Virginia Commonwealth University
Country United States
Scopus ID 59928747600
Documents 10
Citations 15
h-index 2
Subject Area Cardiac Surgery
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0009-0005-6104-0692

Michael Keller is a researcher affiliated with Virginia Commonwealth University whose academic contributions are focused on cardiac surgery, transplantation outcomes, thoracic surgery, and donor organ utilization. His scholarly work demonstrates an emphasis on clinical transplantation research, particularly within heart and lung transplantation, donor selection policies, and postoperative outcomes in cardiothoracic medicine. The researcher has contributed to multiple peer-reviewed publications indexed in Scopus and has participated in collaborative investigations addressing contemporary challenges in transplantation surgery and cardiovascular medicine.[1]

Abstract

The academic contributions of Michael Keller reflect ongoing research activity within the fields of cardiothoracic surgery and transplantation medicine. His publications address clinically significant topics including heart transplantation outcomes, donor organ utilization, lung allograft dysfunction, and transplantation policy assessment. The research profile demonstrates engagement with evidence-based clinical analysis and observational studies designed to improve understanding of transplantation practices and patient outcomes. Through collaborative multidisciplinary investigations, Keller has contributed to literature examining donor quality assessment, transplant eligibility, and post-transplant complications in cardiovascular medicine.[2]

Keywords

  • Cardiac Surgery
  • Heart Transplantation
  • Thoracic Surgery
  • Lung Transplantation
  • Donor Organ Utilization
  • Cardiovascular Medicine
  • Clinical Outcomes Research
  • Transplant Policy

Introduction

Cardiovascular and thoracic transplantation remain highly specialized areas of modern medicine requiring continual investigation into donor selection, postoperative management, and long-term patient outcomes. Researchers in this field contribute to improving clinical protocols and evidence-based transplantation strategies. Michael Keller has participated in scholarly studies that evaluate emerging transplantation policies and the utilization of donor organs in heart and lung transplantation settings.[3] The researcher’s work reflects interest in transplantation medicine within the broader context of cardiovascular surgery and thoracic clinical science. Several publications examine the outcomes associated with donor characteristics and recipient conditions, including hypoxemia, ventricular hypertrophy, diabetes mellitus, and donor circulatory status. These investigations contribute to ongoing discourse regarding transplantation optimization and clinical risk assessment.[4]

Research Profile

Michael Keller is affiliated with Virginia Commonwealth University and has established a developing scholarly profile in cardiac surgery and transplantation research. According to available Scopus indexing data, the researcher has accumulated 15 citations with an h-index of 2, reflecting measurable engagement within the academic literature.[1] The researcher’s publication portfolio includes collaborative investigations published in journals such as The Journal of Heart and Lung Transplantation, The Annals of Thoracic Surgery, Current Challenges in Thoracic Surgery, and Interdisciplinary CardioVascular and Thoracic Surgery. These studies primarily focus on transplant outcomes, donor organ evaluation, and thoracic surgical practices relevant to cardiovascular medicine.[5]

Research Contributions

Keller has contributed to research examining safety-net kidney transplantation after heart transplantation under updated clinical policies. This work evaluates early real-world outcomes associated with policy implementation and explores implications for transplant recipients and healthcare systems.[2] Additional investigations include the assessment of donor left ventricular hypertrophy in heart transplantation and the evaluation of outcomes using organs from hypoxemic donors in heart-lung transplantation. These studies address clinically significant concerns regarding donor suitability and postoperative outcomes in advanced transplantation medicine.[3] Research contributions also extend to lung transplantation outcomes from asphyxiation donors and the influence of preexisting diabetes mellitus on chronic lung allograft dysfunction. These analyses support broader understanding of risk factors and postoperative complications in thoracic transplantation practice.[4]

Publications

  1. Safety-net kidney transplantation after heart transplantation: Early real-world outcomes under the new policy. The Journal of Heart and Lung Transplantation (2026). DOI: 10.1016/j.healun.2026.01.033
  2. Contemporary Outcomes of Heart Transplantation with Moderate-to-Severe Donor Left Ventricular Hypertrophy. The Annals of Thoracic Surgery (2026). DOI: 10.1016/j.athoracsur.2026.03.047
  3. Outcomes and utilization of organs from hypoxemic donors in heart-lung transplantation: an observational study. Current Challenges in Thoracic Surgery (2026). DOI: 10.21037/ccts-2025-1-69
  4. Outcomes of lung transplantation from asphyxiation donors: reassessing hypoxic injury and implications for donation after circulatory death. Interdisciplinary CardioVascular and Thoracic Surgery (2026). DOI: 10.1093/icvts/ivag108
  5. The Impact of Preexisting Diabetes Mellitus on Chronic Lung Allograft Dysfunction After Lung Transplantation. Annals of Thoracic Surgery Short Reports (2026). DOI: 10.1016/j.atssr.2026.02.029

Research Impact

The research activity associated with Michael Keller contributes to contemporary discussions in transplantation surgery and cardiovascular medicine. Published investigations provide clinical insight into donor organ selection, transplantation policy evaluation, and post-transplant outcomes. Such studies support the advancement of evidence-informed decision-making within heart and lung transplantation programs.[5] The citation profile and indexed publications demonstrate emerging academic visibility within cardiothoracic surgical research. Collaborative authorship across multiple peer-reviewed journals indicates interdisciplinary engagement and participation in clinically relevant transplantation studies.[1]

Award Suitability

Michael Keller’s publication profile demonstrates suitability for recognition within the International Research Awards on Cardiology & Cardiovascular Medicine. The researcher’s contributions address clinically important themes in transplantation surgery and cardiovascular medicine, including donor evaluation, transplantation outcomes, and postoperative complications.[2] The combination of indexed publications, measurable citation activity, and participation in peer-reviewed cardiovascular research supports consideration for an innovative research distinction. The work reflects contemporary relevance to cardiac surgery and transplantation science while contributing to evidence-based clinical understanding.[3]

Conclusion

Michael Keller has contributed to the evolving field of cardiac and thoracic transplantation research through collaborative studies addressing donor selection, transplantation outcomes, and postoperative complications. The researcher’s scholarly profile demonstrates continued engagement in clinically relevant cardiovascular investigations published in peer-reviewed journals. These contributions support ongoing advancements in transplantation medicine and provide a foundation for future research within cardiothoracic surgery and cardiovascular healthcare.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Michael Keller, Author ID 59928747600. Scopus. https://www.scopus.com/authid/detail.uri?authorId=59928747600
  2. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Safety-net kidney transplantation after heart transplantation: Early real-world outcomes under the new policy. The Journal of Heart and Lung Transplantation.
    DOI: https://doi.org/10.1016/j.healun.2026.01.033
  3. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Contemporary Outcomes of Heart Transplantation with Moderate-to-Severe Donor Left Ventricular Hypertrophy. The Annals of Thoracic Surgery.
    DOI: https://doi.org/10.1016/j.athoracsur.2026.03.047
  4. Keller, M., Kwon, Y. I. C., Pei, J., et al. (2026). Outcomes and utilization of organs from hypoxemic donors in heart-lung transplantation: an observational study. Current Challenges in Thoracic Surgery.
    DOI: https://doi.org/10.21037/ccts-2025-1-69
  5. Kwon, Y. I. C., Ambrosio, M., Keller, M., et al. (2026). Outcomes of lung transplantation from asphyxiation donors: reassessing hypoxic injury and implications for donation after circulatory death. Interdisciplinary CardioVascular and Thoracic Surgery.
    DOI: https://doi.org/10.1093/icvts/ivag108